NHS Lothian’s successful deployment of NICE
NEVA Assist and NEVA Unattended has resulted in a 50% reduction in
end-to-end triage time
NICE (Nasdaq: NICE)
today announced that NHS Lothian has successfully deployed NICE’s
NEVA Assist and NEVA Unattended in a continuing, multi-year
partnership. These solutions were selected for their proven track
record in large-scale government agencies and an unmatched
combination of attended and unattended automation capabilities.
NHS Lothian provides primary, community-based, and acute
hospital services throughout Scotland. The COVID-19 pandemic
brought to light issues found within the gastroenterology referrals
management system, which caused some patients to wait up to 52
weeks before seeing a specialist. With close to 16,000 new
gastroenterology referrals each year and an increase in urgent
suspected cancer cases, a solution was needed to remove the backlog
and provide better healthcare services.
With the deployment of NICE NEVA Assist and NEVA Unattended, NHS
Lothian reduced its clinical backlog with a 50% reduction in
end-to-end triage time, reformed service quality by freeing
healthcare staff for more value-added tasks, enhanced processing
speed with shorter wait times for patients, and improved accuracy
with a 27% reduction in unnecessary appointments. This success has
inspired process intelligence for evaluating digital
transformations with NHS Lothian working to expand the use of NEVA
to support its broader program of process transformation at the
Health Authority.
Paul Schofield, Head of Digital Innovation for NHS
Lothian, said, “These positive metrics demonstrate the impact
of the NEVA automation allowing us to prove our team’s value, which
is likely to influence decision-making regarding team funding and
size, as well as future projects. NEVA saves clinicians
considerable time and effort, reducing unnecessary appointments and
improving the patient experience. And that, in turn, will lead to
us delivering more for the organization.”
“NICE is thrilled with the success found at NHS Lothian,” said
Darren Rushworth, President, NICE International. “Providing
exceptional patient care is critical. With the deployment of NEVA,
NHS Lothian is positioned for more accurate, swift responses to
health issues that previously took too long to discover. NEVA’s
ability to identify the administrative issues enabled patients to
quickly get the care they need and allowed health care providers to
focus on improving patient care.”
About NHS Lothian NHS Lothian, the second largest Health
Authority in the United Kingdom, provides a comprehensive range of
primary, community-based, and acute hospital services for the
populations of Edinburgh, Midlothian, East Lothian, and West
Lothian. In addition, for patients in the wider region of the
southeast and across Scotland, it provides specialist services that
include liver and kidney transplantation, neonatal intensive care,
cancer services, and complex surgery. NHS Lothian operates 21
hospitals, 126 GP practices, 180 community pharmacies, 173 dental
practices, and 112 ophthalmic practices, with an annual budget of
1.6 billion pounds and approximately 26,000 employees.
www.nhslothian.scot
About NICE With NICE (Nasdaq: NICE), it’s never been
easier for organizations of all sizes around the globe to create
extraordinary customer experiences while meeting key business
metrics. Featuring the world’s #1 cloud native customer experience
platform, CXone, NICE is a worldwide leader in AI-powered
self-service and agent-assisted CX software for the contact center
– and beyond. Over 25,000 organizations in more than 150 countries,
including over 85 of the Fortune 100 companies, partner with NICE
to transform - and elevate - every customer interaction.
www.nice.com
Trademark Note: NICE and the NICE logo are trademarks or
registered trademarks of NICE Ltd. All other marks are trademarks
of their respective owners. For a full list of NICE’s marks, please
see: www.nice.com/nice-trademarks.
Forward-Looking Statements This press release contains
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements, including the statements Mr. Rushworth, are based on
the current beliefs, expectations and assumptions of the management
of NICE Ltd. (the “Company”). In some cases, such forward-looking
statements can be identified by terms such as “believe,” “expect,”
“seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,”
“plan,” “estimate,” or similar words. Forward-looking statements
are subject to a number of risks and uncertainties that could cause
the actual results or performance of the Company to differ
materially from those described herein, including but not limited
to the impact of changes in economic and business conditions,
including as a result of the COVID-19 pandemic; competition;
successful execution of the Company’s growth strategy; success and
growth of the Company’s cloud Software-as-a-Service business;
changes in technology and market requirements; decline in demand
for the Company's products; inability to timely develop and
introduce new technologies, products and applications; difficulties
or delays in absorbing and integrating acquired operations,
products, technologies and personnel; loss of market share; an
inability to maintain certain marketing and distribution
arrangements; the Company’s dependency on third-party cloud
computing platform providers, hosting facilities and service
partners;, cyber security attacks or other security breaches
against the Company; the effect of newly enacted or modified laws,
regulation or standards on the Company and our products and various
other factors and uncertainties discussed in our filings with the
U.S. Securities and Exchange Commission (the “SEC”). For a more
detailed description of the risk factors and uncertainties
affecting the company, refer to the Company's reports filed from
time to time with the SEC, including the Company’s Annual Report on
Form 20-F. The forward-looking statements contained in this press
release are made as of the date of this press release, and the
Company undertakes no obligation to update or revise them, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221101005106/en/
Corporate Media Contact Christopher Irwin-Dudek, +1 201
561 4442, ET, chris.irwin-dudek@nice.com
Investors Marty Cohen, +1 551 256 5354, ET, ir@nice.com
Omri Arens, +972 3 763 0127, CET, ir@nice.com
NICE (NASDAQ:NICE)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
NICE (NASDAQ:NICE)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024